apvac2 vaccine
Vaccineexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2014 (NCT02149225)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1201670 ↗
Also known as
- apvac2 vaccine
- leukine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02149225 | Phase 1 | Oct 1, 2014 | BCN Peptides, Biontech, immatics Biotechnologies GmbH, University of Heidelberg, University of Tuebingen |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BCN Peptides | For profit | 1 | 0 | 1 | 2014 |
| Biontech | For profit | 1 | 0 | 1 | 2014 |
| immatics Biotechnologies GmbH | For profit | 1 | 1 | 1 | 2014 |
| University of Heidelberg | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Tuebingen | Academic/Hospital | 1 | 0 | 1 | 2014 |
5 organizations
Page 1 / 1